SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

9819	Companies
197055	Keywords
128105	Articles
104788	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 04/30/2025 at 13:00, 9 months 6 days ago

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Sanofi and CD&R close Opella transaction, creating global consumer healthcare leader. Sanofi's sale of a 50.0% stake to CD&R marks a strategic move with total net cash proceeds of around €10 billion

Transaction Sanofi CD&R Consumer Healthcare Opella
BRIEF

published on 04/08/2025 at 19:15, 9 months 27 days ago

Sanofi : Publication Positive des Données du Tolebrutinib dans le NEJM

Sclérose En Plaques Sanofi Phase III NEJM Tolebrutinib
BRIEF

published on 04/08/2025 at 19:15, 9 months 27 days ago

Sanofi: Positive Publication of Tolebrutinib Data in NEJM

Multiple Sclerosis Sanofi Phase III NEJM Tolebrutinib
PRESS RELEASE

published on 04/08/2025 at 19:10, 9 months 27 days ago

Communiqué de presse : Publication dans le NEJM de données de phase III illustrant le bénéfice du tolebrutinib sur la progression du handicap dans la sclérose en plaques
Publication dans le NEJM des données de phase III sur l'effet bénéfique du tolebrutinib sur la progression du handicap chez les patients atteints de SEP-SP sans poussées, avec examen réglementaire en cours aux États-Unis et en UE

Sclérose En Plaques Étude De Phase III NEJM Tolebrutinib Handicap
PRESS RELEASE

published on 04/08/2025 at 19:10, 9 months 27 days ago

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 study in NEJM shows delayed disability progression in multiple sclerosis. Potential first therapy targeting immunologic drivers. US priority review ongoing

Multiple Sclerosis Phase 3 NEJM Tolebrutinib Disability Progression
BRIEF

published on 04/03/2025 at 07:05, 10 months 3 days ago

Le rilzabrutinib de Sanofi désigné médicament orphelin aux États-Unis

Sanofi Médicament Orphelin Rilzabrutinib Anémie Hémolytique Maladie Associée Aux IgG4
BRIEF

published on 04/03/2025 at 07:05, 10 months 3 days ago

Sanofi's rilzabrutinib designated an orphan drug in the United States

Sanofi Orphan Drug Rilzabrutinib Hemolytic Anemia IgG4-associated Disease
PRESS RELEASE

published on 04/03/2025 at 07:00, 10 months 3 days ago

Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé
Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares, l'anémie hémolytique à anticorps chauds et la maladie associée aux IgG4, sans traitement approuvé actuellement

FDA Traitement Maladies Rares Médicament Orphelin Rilzabrutinib
PRESS RELEASE

published on 04/03/2025 at 07:00, 10 months 3 days ago

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for warm autoimmune hemolytic anemia and IgG4-related disease, potential use in immune thrombocytopenia. Sanofi's novel BTK inhibitor holds promise for rare diseases

Orphan Drug Designation Sanofi Rare Diseases Rilzabrutinib BTK Inhibitor
BRIEF

published on 03/28/2025 at 21:12, 10 months 8 days ago

FDA Approves Qfitlia for Hemophilia A and B Treatment

FDA Approval Clinical Trials Hemophilia Treatment Antithrombin-lowering Qfitlia

Accesswire

Published on 02/06/2026 at 15:30, 1 hour 34 minutes ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 3 hours 34 minutes ago

Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange
Published on 02/06/2026 at 13:30, 3 hours 34 minutes ago

Canex Metals Acquires 51.93% of Gold Basin and Seeks a Court-Appointed Annual General Meeting of Gold Basin Shareholders
Published on 02/06/2026 at 13:00, 4 hours 4 minutes ago

Revolve Announces US$40 Million Strategic Financing With Callaway Capital
Published on 02/06/2026 at 08:00, 9 hours 4 minutes ago

Caledonia Mining Corporation Plc Non-Executive Director Shareholding Notification

View all ACCESSWIRE

EQS Group

Published on 02/06/2026 at 16:55, 9 minutes ago

GAC MPV Serves as Official Reception Fleet for APEC China 2026, Demonstrating the Strength of Chinese Manufacturing
Published on 02/06/2026 at 15:25, 1 hour 39 minutes ago

CES 2026 Innovation Award Honoree iGarden M1 Pro Max Launches as World's First Bionic Dual-Vision Pool Cleaner
Published on 02/06/2026 at 15:24, 1 hour 40 minutes ago

Form 8.3 - The Vanguard Group, Inc.: NCC Group plc
Published on 02/06/2026 at 15:21, 1 hour 43 minutes ago

Form 8.3 - The Vanguard Group, Inc.: British Land Company plc, The
Published on 02/06/2026 at 15:20, 1 hour 44 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc

Les Echos

Published on 02/06/2026 at 16:01, 1 hour 3 minutes ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 1 hour 3 minutes ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 9 hours 10 minutes ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026
Published on 02/05/2026 at 19:24, 21 hours 40 minutes ago

Minutes of the Combined General Meeting
Published on 02/05/2026 at 19:24, 21 hours 40 minutes ago

Compte-Rendu de l’Assemblée Générale Mixte

View all LES ECHOS COMFI WIRE